Lifevantage (NASDAQ:LFVN) Issues Earnings Results

06 May 2026, 23:06 by Renee Jackson · The Cerbat Gem

Lifevantage (NASDAQ:LFVN – Get Free Report) released its earnings results on Wednesday. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.04), FiscalAI reports. The business had revenue of $43.72 million for the quarter, compared to the consensus estimate of $47.77 million. Lifevantage had a net margin of 3.74% and a return on equity of 29.59%.

Here are the key takeaways from Lifevantage’s conference call:

The company reported net revenue of $43.7 million, down 25.2% year‑over‑year, driven mainly by weaker sales of the MindBody GLP‑1 System and fewer active accounts, and now expects fiscal 2026 results near the lower end of prior guidance.
Profitability pressures included a decline in gross margin to 79% (81% prior year) from higher shipping/warehouse costs and inventory obsolescence, with Q3 GAAP net income falling to $1.4 million ($0.11/share).
Financial position remains solid with $12.5 million cash, no debt, $5.5 million of cash from operations year‑to‑date, an active share repurchase program (board authorized $60 million, ~$59 million remaining), and an 11% higher quarterly dividend of $0.05 per share.
Management is pursuing strategic initiatives to boost growth, including an e‑commerce and back‑office upgrade via Shopify rollout later this year and a newly announced 12‑month VIP bonus incentive aimed at accelerating consultant growth and leadership development.
Product and leadership catalysts include the U.S. patent for the Healthy Glow Essentials Stack, the October convention where a new product launch is planned, the LoveBiome/P84 additions to the portfolio, and the appointment of Terrence Moorehead as CEO joining in August.

Lifevantage Price Performance

Shares of LFVN stock traded up $0.51 during trading hours on Wednesday, reaching $6.00. The stock had a trading volume of 814,778 shares, compared to its average volume of 214,839. The firm has a market capitalization of $76.86 million, a PE ratio of 10.00 and a beta of 0.52. The firm has a 50-day simple moving average of $4.70 and a 200-day simple moving average of $5.81. Lifevantage has a twelve month low of $3.90 and a twelve month high of $15.00.

Insider Transactions at Lifevantage

In other news, Director Judd Dayton bought 18,097 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was purchased at an average price of $4.63 per share, for a total transaction of $83,789.11. Following the transaction, the director owned 69,859 shares in the company, valued at approximately $323,447.17. This trade represents a 34.96% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have bought 38,207 shares of company stock worth $178,585. Insiders own 21.95% of the company’s stock.

Hedge Funds Weigh In On Lifevantage

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its position in Lifevantage by 870.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock valued at $66,000 after acquiring an additional 4,499 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Lifevantage during the second quarter valued at $76,000. BNP Paribas Financial Markets raised its stake in shares of Lifevantage by 2,555.8% during the second quarter. BNP Paribas Financial Markets now owns 6,135 shares of the company’s stock valued at $80,000 after purchasing an additional 5,904 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Lifevantage during the first quarter valued at about $97,000. Finally, New York State Common Retirement Fund acquired a new stake in Lifevantage in the second quarter worth about $102,000. 35.32% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on LFVN shares. Weiss Ratings downgraded shares of Lifevantage from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday. Lake Street Capital restated a “buy” rating on shares of Lifevantage in a research note on Thursday, February 5th. Finally, Loop Capital set a $5.00 price target on Lifevantage in a research report on Thursday, February 5th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Lifevantage has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Check Out Our Latest Stock Report on LFVN

About Lifevantage

(Get Free Report)

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.